Summary Warfarin inhibits metastasis in the animal model and injection of the Warfarin-dependent coagulation factor complex II, IX, X enhances pulmonary metastasis in the same model. We have studied two possible mechanisms responsible for the observed effect.
Evidence from both experimental and clinical studies show a clear relationship between the coagulation system and the spread and growth of malignant disease (Wood, 1958; O'Meara, 1968; Hilgard & Thornes, 1976; Sun et al., 1979; Rickles & Edwards, 1983) . Animal experiments have suggested that the coagulation system may play a role in the blood-borne metastasis of tumour cells (Ryan et al., 1968; Brown, 1973; Wood, 1974; Poggi et al., 1978) . The antimetastatic effect of Warfarin therapy has been demonstrated in several animal experimental models (Ryan et al., 1969; Hilgard et al., 1977; Williamson et al., 1980) .
We have demonstrated the inhibitory effect of Warfarin on pulmonary metastasis in an animal experimental model (McCulloch & George, 1987) . We have also shown, however, that administration of the Warfarin-dependant factor complex II, IX and X enhances pulmonary seeding in a similar model. This effect was not observed on administration of factor VII alone or bovine serum albumin (McCulloch & George, 1988) . The exact mechanism by which factor complex II, IX and X enhances pulmonary tumour cell seeding remains unclear. We are currently investigating a number of possible mechanisms which could explain this observed effect. Amongst the possible explanations considered, were an increase in tumour cell entrapment in the pulmonary capillary bed and an effect on the host immune system caused by injection of xenogeneic (human) proteins.
The present studies were designed to determine the effect of the factor complex on pulmonary entrapment of tumour cells and whether the xenogeneic property of the human factor complex was responsible for the enhancement of pulmonary seeding previously demonstrated. (Neri et al., 1982) from the 7,12-dimethylbenz (a) antracene-induced adenocarcinoma 13762 (Segaloff, 1966) (Neri & Nicholson, 1981 5.0 yCi ml-of medium, with one untreated flask acting as the control. After appropriate dilution and incubation for 8 days under standard conditions, clones were fixed with methanol, stained with crystal violet and surviving colonies counted. Doses of IUDR below 0.07 yCi ml-' were found to have no effect on clonal growth of Mtln3 cells, whereas, clonogenicity was sharply reduced above this concentration.
Materials and methods

Animals
Microtiter assay This assay relies on the ability of live cells to reduce a yellow tetrazolium dye to a purple formazan product. Full details of the method have previously been published (Plumb et al., 1989) . Doses of IUDR below 0.07 ltCi ml-l were found to have no effect on the growth of Mtln3 cells, whereas, higher doses inhibited cell growth. As a result of the above two assays, a dose of 0.05 fLCi ml-' of IUDR was used to label the tumour cells, for the purpose of our experiment.
Rat coagulation factor complex preparation Blood was collected from F344 rats into plastic bottles containing 6% sodium citrate in a ratio of 9:1 v/v. After centrifugation, the fresh rat plasma was processed to isolate factors II, IX and X. A concentrate of rat factor complex II, IX and X was prepared from the plasma by modifying the barium citrate precipitation and ammonium sulphate elution method (Ahmad et al., 1989) , used to prepare human coagulation factor complex II, IX and X. The ratios of the factors II, IX and X varied from 21:10:7 to 11:6:8. For the purposes of this experiment, the batch used had a ratio of 11:6:8. Each rat received a dose of 1 ml of concentrate, containing 11 units of prothrombin, six units of factor IX and eight units of factor X.
Human coagulation factor complex preparation A heat treated concentrate of human coagulation factors II, IX and X, prepared from pooled plasma by cryoprecipitation and supernatant adsorption with DEAE cellulose, was obtained from Dr R.J. Perry of the Protein Fractionation Centre, Edinburgh, UK.
Previous experiments have shown that a dose of six units of prothrombin and factor X, and seven units of factor IX reconstitutes coagulation in a fully warfarinised rat for approximately 12 h. This is the dose of Factor Complex that has been used in all our previous studies wherein we demonstrated the effect of enhancement of tumour metastases (McCulloch & George, 1987) .
To assess whether this effect is dependent on the time of administration or on the concentration of the Factors II, IX and X, the following pilot study was performed:
Seven groups of Female Fisher 344 rats, 6-8 weeks old were used. All animals were injected intravenously with I04 Mtln3 cells as described above. Additional treatments were then commenced as follows: Group A: These control animals received no additional treatment.
Group B: These animals received one injection of Factor Complex II, IX, X (6:7:6 Units), at the same time of tumour cell injection (t = 0). Factor Complex II, IX and X as described above. At the following intervals after injection, three animals per group were exsanguinated, their lungs removed immediately and placed in individual containers containing 70% ethanol: 5,10,30min, 1,6,12 and 18h.
The dose of bovine serum albumin used gave the same protein concentration as the factor complex injection in Group C. The factor complex preparation and the bovine serum albumin were passed through a 0.2 micron filter before injection, for sterilisation and removal of any potentially embolic material.
Lung radioactivity was measured in a gamma counter and expressed as a percentage of the total amount of radioactivity injected. Each sample was counted twice. Comparison of the three groups was by analysis of variance and the Student's t-test. Experiment 2 -Comparison of effect of human and rat factor complexes on pulmonary tumour seeding Three groups of eight Fisher 344 female rats, 6-8 weeks old were used. All animals were injected intravenously with 104 Mtln3 cells as described above. At the same time additional treatments were begun as follows: Group A: These control animals received no additional treatment.
Group B: These animals received one injection of rat factor complex II, IX and X. Group C: These animals received one injection of the human factor complex II, IX and X.
Animals were sacrificed at 17 days and pulmonary seedings assessed by the method of Wexler, as described above. Comparison of the different groups was made by the KruskalWallis Test in conjunction with the Mann-Whitney U Test.
Both experiments were repeated twice.
Results
Pilot studies Human coagulation factor complex: dosage and timing study The dose of Factor Complex II, IX, X used in our previous work was validated, since a 50% reduction in the dose or a 2 h delay in the time of administration of the Factor Complex, resulted in abolition of the effect of enhancement of pulmonary seeding ( Figure 1 ) (P = 0.03, Mann-Whitney). Experiment I In all groups, an initial peak and trough of activity was noted in the first 30 min, which was followed by an exponential decline with time ( Figure 2) . At 1 h, the activity in the factor treated rats (Group C) was 82.84%. This was significantly higher than that in the control (Group A, 62.34%) and that in the rats treated with bovine serum albumin (Group B, 50.10%); (P <0.001 on analysis of variance and Student's t-test, Table II ). This significant difference persisted at all times thereafter. At 1 h, but not thereafter, the difference between groups A and B reached statistical significance (P = 0.018).
Experiment 2
The number of pulmonary nodules in animals treated with rat factor complex (Group B) and with human factor complex (Group C) was significantly higher than that in the control Group A. The median number of tumour seedings was 25 in Group A, 233 in Group B and 226 in Group C (analysis of variance and Mann-Whitney U Test, P<0.001).
There was no significant difference between the experimental groups B and C (P = 0.71), (Figure 3 ). Rat factor complex and human factor complex when administered with tumour cells enhanced pulmonary seeding to a similar degree. 
Discussion
The aim of this study was to identify the process by which factor complex II, IX and X enhances pulmonary seeding. In so doing we hoped to achieve a better understanding of the relationship between the metastatic process and the coagulation system. Such an understanding may have implications in the prevention and treatment of metastatic disease. From our earlier experiments, we know that Warfarin inhibits and injection of factor complex II, IX and X enhances, metastasis in an animal model. Also, injection of factor VII alone or bovine serum albumin does not significantly affect pulmonary seeding and the enhancing effect of the factor complex does not appear to be related to the formation of a fibrin clot. It was also observed that the major role of coagulation in the metastatic process appeared to occur in the first 12 h after tumour cells entered the blood stream. (McCulloch & George, 1987 , 1988 .
In the first experiment, O min after injection of tumour cells, there was a sharp rise in measured radioactivity, in all experimental groups. This could be attributed to recirculation of cells which escaped entrapment on first passage through the pulmonary capillary bed (Fidler, 1970) . At the end of 1 h, the radioactivity measured in the lungs, of animals administered factor complex II, IX and X together with tumour cells, was significantly higher than that in the animals receiving cells alone or cells with bovine serum albumin, a difference that persisted till the end of the experiment at 18 h. This difference can be attributed to increased trapping of tumour cells in the pulmonary microcirculation and may be a contributory factor in producing the effect of enhancement of tumour seeding in our animal model. The exact reason for increased tumour cell entrapment remains unclear. We are currently investigating the possibility that this may be a result of activation of the coagulation system, either partial or complete. Interaction between coagulation factors and platelets may have a role to play here. Platelet aggregation is triggered by thrombin and occurs around entrapped tumour cells, in model systems, within 3 h of tumour cell injection (Sindelar et al., 1975; Crissman et al., 1985) . Platelets have also been shown to enhance adhesion between tumour cells and the endothelial cells (Crissman et al., 1985; Grossi et al., 1987) . The enhancement of tumour seeding seen in our previous experiments could not have been secondary to the xenogeneic property of the human factor complex used since this study shows clearly that both the human and the rat factor complex II, IX and X enhance tumour seeding to a similar degree.
The finding that intravenous injection of coagulation factors enhances metastasis by increasing pulmonary entrapment of tumour cells may, if extended to the human situation, have some implication for the current controversy on the effects of perioperative blood transfusion on survival in cancer patients. Further work is being carried out to determine whether one of the three factors in the factor complex II, IX and X is specifically responsible for enhancing tumour seeding in the lungs.
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